278 Results

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Reidy
    Reidy
  4. Feldman
    Feldman
  5. Hsieh
    Hsieh
  6. Molina
    Molina
  7. Raj
    Raj
  8. Rosenberg
    Rosenberg
  9. Baselga
    Baselga
  10. Abou-Alfa
    Abou-Alfa

Groups

  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (177)
  3. Genitourinary Oncology Service (99)
  4. GSK Faculty (34)
  5. Gastrointestinal Oncology Service (34)
  6. Surgery (33)
  7. Radiology, Department of (31)
  8. Sloan Kettering Institute Postdocs (30)
  9. Department of Pathology and Laboratory Medicine (29)
  10. Center for Pancreatic Cancer Research (27)
  1. "everolimus"
Formats
  1. Journal Article (254)
  2. Review (19)
  3. Editorial (3)
  4. Guidelines (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (177)
  3. Genitourinary Oncology Service (99)
  4. GSK Faculty (34)
  5. Gastrointestinal Oncology Service (34)
  6. Surgery (33)

More Groups

People
  1. Robert Motzer (70)
  2. Martin Voss (19)
  3. Diane Reidy (18)
  4. Jose Baselga (12)
  5. Darren Feldman (10)
  6. James Hsieh (10)

More People

Years
  1. 2025 (7)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (10)
  5. 2021 (12)
  6. 2020 (13)

More Years

Publications
  1. Clinical Cancer Research (21)
  2. Journal of Clinical Oncology (11)
  3. Cancer (10)
  4. Clinical Genitourinary Cancer (10)
  5. Annals of Oncology (9)
  6. Journal of the National Comprehensive Cancer Network (9)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Springer (26)
  3. American Association for Cancer Research (25)
  4. Oxford University Press (19)
  5. Nature Publishing Group (15)
  6. Elsevier Science, Inc. (14)

More Publishers

Results (278)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Journal Article

    Powles, T.; Choueiri, T. K.; Motzer, R. J.; Jonasch, E.; Pal, S.; Tannir, N. M.; Signoretti, S.; Kaldate, R.; Scheffold, C.; Wang, E.; more...
    BMC Cancer (2021)

    Fulltext@MSK | Save
  • Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
    Journal Article

    Curigliano, G.; Martin, M.; Jhaveri, K.; Beck, J. T.; Tortora, G.; Fazio, N.; Maur, M.; Hubner, R. A.; Lahner, H.; Donnet, V.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors
    Journal Article

    Raj, N.; Zheng, Y.; Hauser, H.; Chou, J.; Rafailov, J.; Bou-Ayache, J.; Sawan, P.; Chaft, J.; Chan, J.; Perez, K.; more...
    Endocrine-Related Cancer (2021)

    Fulltext@MSK | Save
  • Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
    Journal Article

    Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Ikezawa, H.; Sachdev, P.; Dutcus, C. E.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma
    Journal Article

    Wright, K. D.; Yao, X.; London, W. B.; Kao, P. C.; Gore, L.; Hunger, S.; Geyer, R.; Cohen, K. J.; Allen, J. C.; Katzenstein, H. M.; more...
    Pediatric Blood and Cancer (2021)

    Fulltext@MSK | Save
  • Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study
    Journal Article

    Gluskin, J.; Plodkowski, A.; Girshman, J.; Sarasohn, D.; Viteri-Jusué, A.; Hayan, S.; Torrisi, J.
    Clinical Imaging (2021)

    Fulltext@MSK | Save
  • Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
    Journal Article

    Tannir, N. M.; Powles, T.; Escudier, B.; Donskov, F.; Grunwald, V.; Sternberg, C. N.; Schmidinger, M.; Schoffski, P.; Szczylik, C.; Peltolta, K.; more...
    Kidney Cancer (2020)

    Fulltext@MSK | Save
  • A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma
    Journal Article

    El Dika, I.; Mayer, R. J.; Venook, A. P.; Capanu, M.; LaQuaglia, M. P.; Kobos, R.; O'Neill, A. F.; Chou, J. F.; Ly, M.; Ang, C.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Journal Article

    Feldman, D. R.; Ged, Y.; Lee, C. H.; Knezevic, A.; Molina, A. M.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Murray, S.; Tickoo, S. K.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
    Review

    Andreatos, N.; Iyer, G.; Grivas, P.
    Cancer Treatment and Research Communications (2020)

    Fulltext@MSK | Save